During the past decade, Texas Oncology, P.A. conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 31 clinical trials were completed, i.e. on average, 129.2% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 13 clinical trials were completed. i.e. 130% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology, P.A." #1 sponsor was "US Oncology Research" with 10 trials, followed by "Bristol-Myers Squibb" with 6 trials sponsored, "Children's Oncology Group" with 4 trials sponsored, "Eisai Inc." with 4 trials sponsored and "CTI BioPharma" with 4 trials sponsored. Other sponsors include 74 different institutions and companies that sponsored additional 62 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology, P.A." #1 collaborator was "Bristol-Myers Squibb" with 5 trials as a collaborator, "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "Pfizer" with 3 trials as a collaborator. Other collaborators include 33 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology, P.A." are "Breast Cancer" (13 trials), "Metastatic Breast Cancer" (7 trials), "Ovarian Cancer" (6 trials), "Prostate Cancer" (6 trials) and "Lung Cancer" (5 trials). Many other conditions were trialed in "Texas Oncology, P.A." in a lesser frequency.

Most popular intervention types in "Texas Oncology, P.A." are "Drug" (98 trials), "Biological" (11 trials), "Other" (4 trials), "Procedure" (3 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (10 trials), "Gemcitabine" (9 trials), "Placebo" (7 trials), "Docetaxel" (6 trials) and "Paclitaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology, P.A." are 74 trials for "All" genders, 23 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology, P.A.". undefined are not yet recruiting, 5 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 69 completed trials in Texas Oncology, P.A., undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology, P.A., 14 "Phase 1" clinical trials were conducted, 48 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".